Dr. Berenson is a highly accomplished medical professional and visionary leader in the field of oncology. As the Founder and Principal of ONCOtherapeutics, a renowned specialty practice in West Hollywood, CA, he has dedicated his career to providing exceptional care to patients with multiple myeloma and related malignancies and conditions. With a patient roster exceeding 600 individuals, Dr. Berenson has made a significant impact on the lives of many.
In addition to his role at ONCOtherapeutics, Dr. Berenson holds the position of CEO at ONCOtherapeutics, a specialized Contract Research Organization that spearheads preclinical research and clinical trials across all phases, from I to IV, in community oncology sites across the United States. This multidimensional approach allows him to bridge the gap between research and practice, bringing cutting-edge treatments to the patients who need them.
Dr. Berenson’s commitment to advancing the treatment of myeloma led him to establish the Institute for Myeloma & Bone Cancer Research (IMBCR), a mission-driven 501(C)3 non-profit institute. IMBCR focuses on fostering scientific innovation to achieve personalized and continuous optimized patient care. Through the institute, Dr. Berenson aims to connect possibility and drive progress in the field of myeloma treatment.
With a prolific career, Dr. Berenson has authored over 300 peer-reviewed publications and has contributed to multiple book chapters, solidifying his expertise in the field. Recognized for his exceptional knowledge and insights, he serves as a member of the National Institutes of Health – Center for Scientific Review, Clinical Oncology Study Section. Dr. Berenson also holds positions on the Scientific Boards of esteemed organizations such as the Multiple Myeloma Research Foundation, the International Myeloma Foundation, and the Leukemia, Lymphoma, and Myeloma Society, where he serves on both the Foundation and Scientific Boards.
Dr. Berenson’s tireless dedication, innovative research, and contributions to the field of oncology have made him a respected figure in the medical community. His unwavering commitment to improving patient care and advancing the understanding of multiple myeloma continues to positively impact the lives of countless individuals.